Keeping Track: Provention Teplizumab, AZ Anifrolumab Headline Submissions; AZ Brilinta Gains Stroke Risk Reduction Claim

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

Two novel biologics license application (BLA) submissions lead the US FDA review and approval news this week, one from pharma giant AstraZeneca PLC and one from relative newcomer Provention Bio, Inc., while AbbVie Inc.’s Rinvoq and Johnson & Johnson/Bayer AG’s Xarelto were submitted for new indications. Ophthalmic specialist Santen Pharmaceutical Co., Ltd.’s bid for approval for an eye drop formulation of the immunosuppressant cyclosporine.

Meanwhile, the quiet season for FDA approvals continues. The agency cleared a new indication for AstraZeneca’s direct oral anticoagulant Brilinta...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers